Correction: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies

Oncogene 2026 Open access

Read full text

Authors: J. Zhou, J. Luo, Kaijie Wu, E-j Yun, Payal Kapur, R C Pong, Y. Du, B. Wang, Craig Authement, E. Hernandez, J. Yang, Guanghua Xiao

+8 more

T.-L. Cha, H-C Wu, D. Wu, Vitaly Margulis, Yair Lotan, James Brugarolas, D. He, J-T Hsieh

DOI: 10.1038/s41388-026-03721-z

Cited by: 0

Fields of Study & Subjects

PI3K/AKT/mTOR signaling in cancer Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers